Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants.

[1]  M. Snape,et al.  Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action. , 2014, The Lancet. Infectious diseases.

[2]  Mark M. Davis,et al.  CD4+ T Cell Autoimmunity to Hypocretin/Orexin and Cross-Reactivity to a 2009 H1N1 Influenza A Epitope in Narcolepsy , 2013, Science Translational Medicine.

[3]  Sebastiaan Overeem,et al.  Clinical, polysomnographic and genome‐wide association analyses of narcolepsy with cataplexy: a European Narcolepsy Network study , 2013, Journal of sleep research.

[4]  K. Gautvik,et al.  Incidence of narcolepsy in Norwegian children and adolescents after vaccination against H1N1 influenza A. , 2013, Sleep medicine.

[5]  A. Pariente,et al.  Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France. , 2013, Brain : a journal of neurology.

[6]  D. Salmon,et al.  Editorial commentary: Guillain-Barré syndrome and vaccinations. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  E. Lewis,et al.  Lack of association of Guillain-Barré syndrome with vaccinations. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  P. Yang,et al.  Influenza vaccination coverage rates among adults before and after the 2009 influenza pandemic and the reasons for non-vaccination in Beijing, China: A cross-sectional study , 2013, BMC Public Health.

[9]  E. Mignot,et al.  Genetic association, seasonal infections and autoimmune basis of narcolepsy. , 2013, Journal of autoimmunity.

[10]  A. Falsey,et al.  AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. , 2013, The Lancet. Infectious diseases.

[11]  J. Ledgerwood.  AS03-adjuvanted influenza vaccine in elderly people. , 2013, The Lancet. Infectious diseases.

[12]  A. Crucitti,et al.  Is the adjuvant solely to blame? , 2013, BMJ : British Medical Journal.

[13]  N. Darín,et al.  Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination , 2013, Neurology.

[14]  E. Mignot,et al.  Decreased incidence of childhood narcolepsy 2 years after the 2009 H1N1 winter flu pandemic , 2013, Annals of neurology.

[15]  N. Andrews,et al.  Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis , 2013, BMJ : British Medical Journal.

[16]  F. Augustovski,et al.  Influenza A/H1N1 MF59 adjuvanted vaccine in pregnant women and adverse perinatal outcomes: multicentre study , 2013, BMJ : British Medical Journal.

[17]  M. de Vincentiis,et al.  Bell's palsy and autoimmunity. , 2012, Autoimmunity reviews.

[18]  T. Heikkinen,et al.  Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study. , 2012, American journal of obstetrics and gynecology.

[19]  Thomas Krucker,et al.  Nonviral delivery of self-amplifying RNA vaccines , 2012, Proceedings of the National Academy of Sciences.

[20]  E. De Gregorio,et al.  The mechanism of action of MF59 - an innately attractive adjuvant formulation. , 2012, Vaccine.

[21]  T. Lambe.  Novel Viral Vectored Vaccines for the Prevention of Influenza , 2012, Molecular medicine.

[22]  K. Johansen,et al.  A collaborative approach to investigating the risk of thrombocytopenic purpura after measles-mumps-rubella vaccination in England and Denmark. , 2012, Vaccine.

[23]  D. Wuttke,et al.  The role of adjuvant in mediating antigen structure and stability. , 2012, Journal of pharmaceutical sciences.

[24]  M. Partinen,et al.  Increased Incidence and Clinical Picture of Childhood Narcolepsy following the 2009 H1N1 Pandemic Vaccination Campaign in Finland , 2012, PloS one.

[25]  S. Himanen,et al.  AS03 Adjuvanted AH1N1 Vaccine Associated with an Abrupt Increase in the Incidence of Childhood Narcolepsy in Finland , 2012, PloS one.

[26]  S. Esposito,et al.  Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis. , 2012, Vaccine.

[27]  T. Tsai.  MF59 adjuvanted seasonal and pandemic influenza vaccines. , 2011, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[28]  R. Manetti,et al.  Infectious diseases and autoimmunity. , 2011, Journal of infection in developing countries.

[29]  S. Esposito,et al.  Different influenza vaccine formulations and adjuvants for childhood influenza vaccination. , 2011, Vaccine.

[30]  E. Mignot,et al.  Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in china , 2011, Annals of neurology.

[31]  I. Nazareth,et al.  Pregnancy and safety outcomes in women vaccinated with an AS03-adjuvanted split virion H1N1 (2009) pandemic influenza vaccine during pregnancy: a prospective cohort study. , 2011, Vaccine.

[32]  D. Weiner,et al.  Clinical applications of DNA vaccines: current progress. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  R. Coffman,et al.  Assessing the Safety of Adjuvanted Vaccines , 2011, Science Translational Medicine.

[34]  I. Grotto,et al.  Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases , 2011, Arthritis care & research.

[35]  N. Garçon,et al.  The safety evaluation of adjuvants during vaccine development: the AS04 experience. , 2011, Vaccine.

[36]  C. Combescure,et al.  Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. , 2011, Arthritis and rheumatism.

[37]  J. Yewdell,et al.  MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines , 2011, Science Translational Medicine.

[38]  Ming Li,et al.  Presentations of primary hypersomnia in Chinese children. , 2011, Sleep.

[39]  F. Mosca,et al.  Influenza A/H1N1 MF59-Adjuvanted Vaccine in Preterm and Term Children Aged 6 to 23 Months , 2011, Pediatrics.

[40]  P. Chomez,et al.  Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. , 2011, Vaccine.

[41]  R. Rappuoli,et al.  Influenza vaccine immunology , 2011, Immunological reviews.

[42]  Xiong He,et al.  Estimates of the True Number of Cases of Pandemic (H1N1) 2009, Beijing, China , 2010, Emerging infectious diseases.

[43]  Noni E MacDonald,et al.  Influenza pandemic planning and performance in Canada, 2009. , 2010, Canadian journal of public health = Revue canadienne de sante publique.

[44]  P. van Damme,et al.  AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[45]  Sebastiaan Overeem,et al.  Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy , 2010, Nature Genetics.

[46]  G. Leroux-Roels,et al.  Unmet needs in modern vaccinology: adjuvants to improve the immune response. , 2010, Vaccine.

[47]  J. Dalmau,et al.  Antibodies and neuronal autoimmune disorders of the CNS , 2010, Journal of Neurology.

[48]  F. Ansaldi,et al.  MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk , 2010, Expert opinion on biological therapy.

[49]  N. Groth,et al.  MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. , 2009, Vaccine.

[50]  T. Vesikari,et al.  MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. , 2009, Vaccine.

[51]  S. Plotkin,et al.  Vaccines: the Fourth Century , 2009, Clinical and Vaccine Immunology.

[52]  P. Foley.  Encephalitis lethargica and the influenza virus. II. The influenza pandemic of 1918/19 and encephalitis lethargica: epidemiology and symptoms , 2009, Journal of Neural Transmission.

[53]  T. Vesikari,et al.  Enhanced Immunogenicity of Seasonal Influenza Vaccines in Young Children Using MF59 Adjuvant , 2009, The Pediatric infectious disease journal.

[54]  C. Gieger,et al.  Narcolepsy is strongly associated with the TCR alpha locus , 2009, Nature Genetics.

[55]  S. Nevsimalova,et al.  Narcolepsy in childhood. , 2009, Sleep medicine reviews.

[56]  Michele A. Kutzler,et al.  DNA vaccines: ready for prime time? , 2008, Nature Reviews Genetics.

[57]  S. Gilman,et al.  The relationship between encephalitis lethargica and influenza: A critical analysis , 2008, Journal of NeuroVirology.

[58]  Seockhoon Chung,et al.  Prevalence of narcolepsy‐cataplexy in Korean adolescents , 2008, Acta neurologica Scandinavica.

[59]  D. Picchioni,et al.  A Case-Control Study of the Environmental Risk Factors for Narcolepsy , 2007, Neuroepidemiology.

[60]  A. Baxter,et al.  The origin and application of experimental autoimmune encephalomyelitis , 2007, Nature Reviews Immunology.

[61]  P. Chomez,et al.  GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives , 2007, Expert review of vaccines.

[62]  S. Gilman,et al.  Children and encephalitis lethargica: a historical review. , 2007, Pediatric neurology.

[63]  R. Jacobson,et al.  Immunosenescence: role and measurement in influenza vaccine response among the elderly. , 2007, Vaccine.

[64]  L. Stojanovich.  Influenza Vaccination of Patients With Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA) , 2006, Clinical & developmental immunology.

[65]  S. Swedo,et al.  Streptococcal mimicry and antibody-mediated cell signaling in the pathogenesis of Sydenham's chorea , 2006, Autoimmunity.

[66]  R. Couch.  Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy. , 2004, The New England journal of medicine.

[67]  Robert T. Chen,et al.  Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. , 2004, The New England journal of medicine.

[68]  M. Goldman,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Vaccination and Autoimmune Disease: What Is the Evidence? , 2022 .

[69]  C. Berek,et al.  Analysis of the presence of Trypanosoma cruzi in the heart tissue of three patients with chronic Chagas' heart disease. , 2003, The American journal of tropical medicine and hygiene.

[70]  J. Bach,et al.  The effect of infections on susceptibility to autoimmune and allergic diseases. , 2002, The New England journal of medicine.

[71]  A. Osterhaus,et al.  Cross-reactive anti-galactocerebroside antibodies and Mycoplasma pneumoniae infections in Guillain–Barré syndrome , 2002, Journal of Neuroimmunology.

[72]  N. Rose,et al.  Type 1 diabetes: virus infection or autoimmune disease? , 2002, Nature Immunology.

[73]  V. Pankratz,et al.  The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study. , 2002, Sleep.

[74]  G. Giovannoni,et al.  Poststreptococcal acute disseminated encephalomyelitis with basal ganglia involvement and auto‐reactive antibasal ganglia antibodies , 2001, Annals of neurology.

[75]  E. Mignot.  A hundred years of narcolepsy research. , 2001, Archives italiennes de biologie.

[76]  N Risch,et al.  Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. , 2001, American journal of human genetics.

[77]  Sebastiaan Overeem,et al.  A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains , 2000, Nature Medicine.

[78]  I. Mackay,et al.  Molecular mimicry: a critical look at exemplary instances in human diseases , 2000, Cellular and Molecular Life Sciences CMLS.

[79]  Sebastiaan Overeem,et al.  Hypocretin (orexin) deficiency in human narcolepsy , 2000, The Lancet.

[80]  N. Restifo,et al.  DNA and RNA-based vaccines: principles, progress and prospects. , 1999, Vaccine.

[81]  S. Modrow,et al.  Acute parvovirus B19 infection in connection with a flare of systemic lupus erythematodes in a female patient. , 1999, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[82]  A. Sette,et al.  Microbial Epitopes Act as Altered Peptide Ligands to Prevent Experimental Autoimmune Encephalomyelitis , 1999, The Journal of experimental medicine.

[83]  N. Rose,et al.  The role of infection in the pathogenesis of autoimmune disease. , 1998, Seminars in immunology.

[84]  L. Steinman,et al.  More mayhem from molecular mimics , 1997, Nature Medicine.

[85]  J. Strominger,et al.  Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients. Identity of key contact residues in the B-cell and T-cell epitopes. , 1997, The Journal of clinical investigation.

[86]  John W. Glasser,et al.  Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team. , 1997, Pediatrics.

[87]  L Steinman,et al.  Multiple Sclerosis: A Coordinated Immunological Attack against Myelin in the Central Nervous System , 1996, Cell.

[88]  P. A. Schad,et al.  Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[89]  A. McDonald,et al.  Lipopolysaccharides from Campylobacter jejuni associated with Guillain-Barré syndrome patients mimic human gangliosides in structure , 1994, Infection and immunity.

[90]  A. Steere,et al.  Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis. , 1994, The New England journal of medicine.

[91]  C Bona,et al.  Defining criteria for autoimmune diseases (Witebsky's postulates revisited) , 1993, Immunology today.

[92]  J. Coura,et al.  [The evolution of chronic chagasic cardiopathy. I. The influence of parasitemia]. , 1992, Revista da Sociedade Brasileira de Medicina Tropical.

[93]  C. P. Maurizi.  Influenza caused epidemic encephalitis (encephalitis lethargica): the circumstantial evidence and a challenge to the nonbelievers. , 1989, Medical hypotheses.

[94]  Ji-Woon Yoon,et al.  ASSOCIATION OF CYTOMEGALOVIRUS INFECTION WITH AUTOIMMUNE TYPE 1 DIABETES , 1988, The Lancet.

[95]  A. Steere,et al.  The clinical evolution of Lyme arthritis. , 1987, Annals of internal medicine.

[96]  P. Schur,et al.  Influenzal vaccine response in systemic lupus erythematosus. , 1978, Annals of internal medicine.

[97]  P. Palese,et al.  Genetic composition of a high-yielding influenza A virus recombinant: a vaccine strain against "Swine" influenza. , 1976, Science.

[98]  C. Hunter.  THE LATE SEQUELAE OF ENCEPHALITIS LETHARGICA AND OF INFLUENZA. , 1931, Canadian Medical Association journal.

[99]  Alexander Jb.  Cases Resembling Encephalitis Lethargica occurring during the Influenza Epidemic. , 1919 .

[100]  J. R. Caldwell,et al.  A REPORT ON TWO CASES OF ENCEPHALITIS LETHARGICA , 1919, British medical journal.

[101]  M. Kontić,et al.  Influenza vaccination in autoimmune rheumatic disease patients. , 2013, The Tohoku journal of experimental medicine.

[102]  R. Rappuoli,et al.  60 – Technologies for making new vaccines , 2013 .

[103]  Gerald van Belle,et al.  The epidemiology of narcolepsy. , 2007, Sleep.

[104]  I. Smith,et al.  Factors associated with a delay in the diagnosis of narcolepsy. , 2004, Sleep medicine.

[105]  S. A. Wilson,et al.  Disorders of motility and muscle tone with special reference to the corpus striatum , 1925 .

[106]  C. Economo.  Die Encephalitis lethargica , 1918 .